Video

Dr. Mamounas on Recurrence Rates in Breast Cancer

Terry P. Mamounas, MD, MPH, FACS, discusses common recurrence rates in breast cancer.

Eleftherios (Terry) P. Mamounas, MD, MPH, FACS, medical director of the Comprehensive Breast Program at the University of Florida Health Cancer Center, discusses common recurrence rates in breast cancer.

When it comes to early stage estrogen receptor (ER)–positive breast cancer, over time, the risk of recurrence is generally stable, says Mamounas. Conversely, with triple-negative breast cancer, the risk of reoccurrence is high in the first 2 to 3 years but, after 5 plus years, it can drop to nearly 0%. 

However, for patients with ER-positive breast cancer, several studies demonstrated that the rate of risk of recurrence and death are typically the highest after the first 5 years, Mamounas adds. 

As shown in larger studies, the rate of distant recurrence is stable from year 5 to 20; however, this depends, to some extent, on the original tumor presentation. Regardless, this is a remarkable rate, Mamounas concludes.

Related Videos
Albert Grinshpun, MD, MSc, head, Breast Oncology Service, Shaare Zedek Medical Center
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Stephanie Graff, MD, and Chandler Park, FACP
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine
Maxwell Lloyd, MD, clinical fellow, medicine, Department of Medicine, Beth Israel Deaconess Medical Center
Neil Iyengar, MD, and Chandler Park, MD, FACP
Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute
Rena Callahan, MD, and Chandler Park, MD, FACP
Hope S. Rugo, MD, FASCO, Winterhof Family Endowed Professor in Breast Cancer, professor, Department of Medicine (Hematology/Oncology), director, Breast Oncology and Clinical Trials Education; medical director, Cancer Infusion Services; the University of California San Francisco Helen Diller Family Comprehensive Cancer Center
Virginia Kaklamani, MD, DSc, professor, medicine, Division of Hematology-Medical Oncology, The University of Texas (UT) Health Science Center San Antonio; leader, breast cancer program, Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center